Latest Headlines

  1. Novartis Breaks Ground On New Global Biomedical Research Center In San Diego To Accelerate Drug Discovery 2/6/2026

    Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients.

  2. IU Drug Discovery Initiative Helps Researchers Move Cancer Drugs From The Lab To Patients 2/5/2026

    An initiative at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center is helping researchers move early-stage drug discoveries from the lab to clinical applications that could transform cancer care and advance progress toward cancer cures.

  3. Biochemists Establish New Method For Identifying Pharmaceutical Candidates Faster 2/5/2026

    A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the lab that could lead to more effective pharmaceuticals.

  4. XtalPi Convenes Global Experts To Shape The Future Of Molecular Glue Drug Discovery: From Serendipity To Precision 2/5/2026

    Recently, XtalPi, a global leader in AI- and robotics-powered drug discovery, successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery. The event convened leading scientists, biopharma innovators, entrepreneurs, and investors from around the world to explore how emerging technologies are redefining strategies for historically "undruggable" protein targets.

  5. BioSelective Capital Investments Completes Acquisition Of BioDuro's Irvine, California Drug Product Development And Manufacturing Operations 2/4/2026

    BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, resulting in the formation of Forma Life Sciences, Inc. (FORMA), a Delaware corporation established to hold and operate the acquired assets.

  6. Zonsen PepLib Biotech Enters Global R&D Collaboration And License Agreement With Lilly 2/3/2026

    Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered a global research and development (R&D) collaboration and license agreement with Eli Lilly and Company ("Lilly").

  7. New Boron Compounds Pave The Way For Easier Drug Development 2/3/2026

    A major step towards simpler drug development has been taken at the University of Gothenburg. In a new study, researchers have developed stable boron-fluorine compounds that make it possible to increase the effect or reduce side effects without breaking down the medicine.

  8. Exelixis Announces U.S. FDA Accepted The New Drug Application For Zanzalintinib In Combination With An Immune Checkpoint Inhibitor For Patients With Metastatic Colorectal Cancer 2/2/2026

    Exelixis, Inc. today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq), has been accepted for review in the U.S. for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. The Food and Drug Administration (FDA) assigned a standard review with a Prescription Drug User Fee Act target action date of December 3, 2026.

  9. Lupin And TB Alliance Join Forces To Advance Telacebec For The Treatment Of Tuberculosis And Other Mycobacterial Diseases 2/2/2026

    Global pharma major Lupin Limited (Lupin) today announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203), for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer.

  10. TuHURA Biosciences Received FDA Orphan Drug Designation For IFx-2.0 For The Treatment Of Stage IIB To Stage IV Cutaneous Melanoma 2/2/2026

    TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma.